Form 4: Atea Pharmaceuticals CEO Sells Shares
SEC Filing
Jean-Pierre Sommadossi, President, CEO, and Chairman of Atea Pharmaceuticals, Inc., sold 1,006 shares of common stock on June 5, 2024.
Summary
- Jean-Pierre Sommadossi, the President, CEO, and Chairman of Atea Pharmaceuticals, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction where Mr. Sommadossi sold 1,006 shares of Atea Pharmaceuticals' common stock on June 5, 2024, at a price of $4 per share.
- Following the transaction, Mr. Sommadossi directly owns 116,557 shares and indirectly owns 5,923,994 shares through JPM Partners LLC.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by the CEO. It doesn't inherently convey positive or negative sentiment, but the market may interpret the sale as a lack of confidence.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for signals about management's view of the company's prospects.
Stakeholder Impact
- Shareholders may react to the stock sale, potentially impacting the stock price.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock sale transaction |
| 06/07/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.